Scott + Scott, LLP Notifies Investors of Monday, March 14, 2016 Deadline in Esperion Therapeutics (ESPR) Securities Case

NEW YORK--()--Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.

“remains on track to initiate the ETC-1002 Phase 3 development program by the end of 2015”

About the Lawsuit

Esperion is a pharmaceutical company that focuses on developing and commercializing oral low-density lipoprotein cholesterol ("LDL-cholesterol") lowering therapies. The securities lawsuit alleges that Esperion issued a press release on August 17, 2015 about its lead product candidate, ETC-1002, that was false and was in conflict with a September 28, 2015 press release.

On August 17, 2015, Esperion stated that it "remains on track to initiate the ETC-1002 Phase 3 development program by the end of 2015" and that, "[b]ased on feedback from the FDA, approval of ETC-1002 in the HeFH and ASCVD patient populations will not require the completion of a cardiovascular outcomes trial (CVOT)."

On September 28, 2015, Esperion stated that "[f]or patients on maximally tolerated statin therapy who require additional LDL-C lowering, Esperion will plan to conduct efficacy and long-term safety trials. FDA has encouraged the Company to initiate a cardiovascular outcomes trial promptly … since any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before approval."

On this news, shares of the Company's stock declined $16.76 per share, or over 47%, to close on September 29, 2015 at $18.33 per share.

What you can do

If you purchased shares of Esperion stock, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (866) 326-5057 or by email at gjohnson@scott-scott.com or jhalloran@scott-scott.com.

About Scott + Scott, Attorneys at Law, LLP

Scott + Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio.

Contacts

Scott+Scott, Attorneys at Law, LLP
Geoffrey M. Johnson, Esq., gjohnson@scott-scott.com
Joseph Halloran, Esq., jhalloran@scott-scott.com
216-229-6088
toll-free 866-326-5057

Recent Stories

RSS feed for Scott+Scott, Attorneys at Law, LLP

Scott+Scott, Attorneys at Law, LLP